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Genetic or Pharmacological Iron Chelation
Prevents MPTP-Induced Neurotoxicity In Vivo:
A Novel Therapy for Parkinson’s Disease
Introduction
Iron levels in the substantia nigra (SN), the dopamine-
containing region of the brain that undergoes selective
degeneration in Parkinson’s disease (PD), have been
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reported to be elevated in patients with the disorderIrene Volitaskis,6 Lisa Ellerby,1 Robert A. Cherny,6
(Sofic et al., 1988, 1991; Dexter et al., 1987, 1989; YoudimAshley I. Bush,6,7 and Julie K. Andersen1,2,*
et al., 1993; Gerlach et al., 1994; Yantiri and Andersen,1Buck Institute for Age Research
1999; Griffiths et al., 1999; Andersen, 2001). AccessibleNovato, California 94945
ferrous iron (Fe2) can react with hydrogen peroxide2 Division of Neurogerontology
(H2O2) produced during oxidative deamination of dopa-Andrus Gerontology Center
mine to generate hydroxyl radicals (·OH) that can dam-University of Southern California
age proteins, nucleic acids, and membrane phospho-Los Angeles, California 90089
lipids, leading to cellular degeneration (Beal, 1992;3 Biological Imaging Center
Gutteridge, 1992). However, whether the increase in SNCalifornia Institute of Technology
iron is a causal factor in the disease or a consequencePasadena, California 91125
itself of neuronal degeneration is controversial (Adams4 Department of Neurology and Neuroscience
and Odunze, 1991; Berg et al., 2001; Thompson et al.,
Weill Medical College of Cornell University
2001). Experiments were therefore undertaken to test
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whether iron is causally involved in cellular degeneration5 The Parkinson’s Institute associated with toxin-induced parkinsonism by as-
Sunnyvale, California 94089 sessing whether iron chelation can act to protect against
6 Department of Pathology dopaminergic cell loss.
The University of Melbourne In the first set of experiments, susceptibility of trans-
The Mental Health Research Institute of Victoria genic mice expressing the ferritin heavy subunit (H ferri-
Parkville 3052 tin) within dopaminergic SN neurons to the PD-inducing
Australia neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
7 Laboratory of Oxidation Biology (MPTP) was assessed. Ferritin, the primary nonheme
Genetics and Aging Research Unit iron storage molecule in the body, can sequester up
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Harvard Medical School (Harrison and Arosio, 1996). Ferritin is believed to keep
Massachusetts General Hospital iron in a nonreactive form where it cannot promote redox
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protecting tissues against iron-catalyzed oxidative dam-
age (Jellinger, 1999). The ferroxidase activity of H ferritin
converts harmful labile ferrous iron to less soluble, unre-
active ferric iron, while the light subunit (L ferritin)Summary
stablizes the ferritin-iron complex, promoting long-term
iron storage (Harrison and Arosio, 1996; Rucker et al.,Studies on postmortem brains from Parkinson’s pa-
1996). In the second set of experiments, mice were orallytients reveal elevated iron in the substantia nigra (SN).
pretreated for 8 weeks with the antibiotic 5-chloro-7-Selective cell death in this brain region is associated
iodo-8-hydroxyquinoline (clioquinol or CQ) and as-with oxidative stress, which may be exacerbated by
sessed for the ability of the compound to protect againstthe presence of excess iron. Whether iron plays a
MPTP-induced toxicity. Another antibiotic compound,causative role in cell death, however, is controversial.
minocycline, has previously been demonstrated to pro-
Here, we explore the effects of iron chelation via either tect against MPTP toxicity, likely due to its ability to
transgenic expression of the iron binding protein fer- decrease nitric oxide-mediated apoptosis (Du et al.,
ritin or oral administration of the bioavailable metal 2001). CQ’s mechanism of action, however, is likely dif-
chelator clioquinol (CQ) on susceptibility to the Parkin- ferent. It has been shown to chelate both ferrous and
son’s-inducing agent 1-methyl-4-phenyl-1,2,3,6-tetra- ferric iron (Kidani et al., 1974) and to decrease brain
pyridine (MPTP). Reduction in reactive iron by either iron levels in normal mice (Yassin et al., 2000). Its oral
genetic or pharmacological means was found to be administration was reported to inhibit -amyloid accu-
well tolerated in animals in our studies and to result mulation in an Alzheimer’s disease (AD) transgenic
in protection against the toxin, suggesting that iron mouse model via its actions as a metal chelator (Huang
chelation may be an effective therapy for prevention et al., 1999; Bush, 2000; Cherny et al., 2001). In addition,
in a recently reported small two-year double-blind hu-and treatment of the disease.
man phase II clinical trial, it has been reported to be
well tolerated in patients and to delay the course of the
disease by 9 months (Masters, 2002). Neither ferritin*Correspondence: jandersen@buckinstitute.org
8 These authors contributed equally to this work. expression nor oral CQ treatment appear to elicit any
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Figure 1. Creation of pTH-Ferritin Transgenics
(A) Schematic of pTH-ferritin construct used for creation of ferritin transgenics and Xba I-EcoRI probe used for Southern analysis. Abbreviations:
pTH, 4.8 kb 5 rat tyrosine hydroxylase promoter region; human ferritin H-chain, human ferritin heavy chain 2.6 kb genomic fragment; SV40/
poly A, 900 bp 3 large T antigen SV40 splice/polyadenylation sequences; probe, 32P-labeled Xba I/EcoRI cDNA fragment of ferritin H-chain.
(B) Representative Southern blot analysis of genomic tail DNA isolated from pTH-ferritin founders. Lanes 1 and 2, transgenics; lanes 3–5,
nontransgenics; lane 6, 2.6 kb Xba I/EcoRI ferritin probe.
(C) Representative Western blot using monoclonal antibody directed against human H ferritin. Abbreviations: Tg, ferritin transgenic; wt, wild-
type littermate. Arrow shows expected position of the 21 kDa human ferritin H-chain protein.
(D) Expression of human ferritin protein product in dopaminergic SN neurons verified by representative double immunocytochemistry (ICC)
using H ferritin and TH antibodies. Images 1–3, ICC with monoclonal antibody against human H ferritin (hFh dilution, 1:500); images 4–6, ICC
with TH antibody (dilution, 1:500). 1 and 4, 10 magnification; 2, 3, 5 and 6, 20 magnification.
apparent adverse general health or behavioral effects, SN of resulting lines was verified by both Western blot
analysis (Figure 1C) and immunocytochemistry (ICC;unlike chelators currently used as therapy for iron over-
load conditions, which can have severe side effects Figure 1D, 1–3). No changes were observed in endoge-
nous ferritin levels in these animals (data not shown).(Porter and Huehns, 1989; Marciani et al., 1991). Results
from our studies demonstrate that such in vivo iron che- Double labeling of H ferritin-expressing cells with tyro-
sine hydroxylase (TH) antibody demonstrated that thelation protects mice against the toxic effects of the par-
kinsonian-inducing agent MPTP and suggest that this transgenic ferritin protein is localized within dopaminer-
gic SN neurons (Figure 1D, 4–6). Adult ferritin trans-may be a novel avenue of therapy for the disease.
genics exhibited no overt phenotype, reproduced nor-
mally, and displayed no gross alterations in brain sizeResults
or anatomical features in histologically stained brain
sections (data not shown).Transgenic ferritin lines were generated by injection of
an 8.3 kb DNA fragment into fertilized mouse embryos Increased iron binding to ferritin would be expected
to result in increased conversion of ferrous to ferric ironcontaining the rat tyrosine hydroxylase promoter (pTH)
driving expression of the human H ferritin gene (Figure as it enters the ferritin core and is oxidized to ferrihydrite.
Ferric iron’s paramagnetic characteristics allow for its1A). Human ferritin binds iron more tightly than the
mouse isoforms, making it a superior iron chelating visualization by high-field magnetic resonance imaging
(MRI); the signal is intensified when iron is bound toagent, and monoclonal antibodies are also available that
are specific to the human protein (Rucker et al., 1996). ferritin and thereby can be used as a measure of ferritin
bound iron (Gilissen et al., 1998; Griffiths et al., 1999).In order to prevent iron-induced downregulation of
transgenic ferritin RNA translation, the 5 noncoding re- MRI was performed on brains from ferritin transgenics
versus nontransgenic littermates and the signal intensitygion of the gene containing an iron-response element
(IRE) was excluded from the construct (Caughman et quantified using frontal cortex as an internal control. A
33.7% 8.5% increase in signal intensity was observedal., 1988).
Integration of the pTH-ferritin transgene in founder in transgenic animals versus wild-type controls (Figure
2A; n  4 animals per parameter, p  0.01). Conversely,animals was verified by Southern blot analysis (Figure
1B). Expression of the human H ferritin protein in the bioavailable SN ferrous iron levels were found to be
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Figure 2. Levels and Localization of Ferric/
Ferrous Iron in the SN of pTH-Ferritin Trans-
genics versus Wild-Type Littermates
(A) Representative MRI analysis of brains
from ferritin transgenics versus wild-type ani-
mals demonstrating levels of ferritin bound
ferric iron; n  4 for each group. Abbrevia-
tions: SN, substantia nigra; wt, wild-type; Tg,
transgenic.
(B) Bioavailable SN ferrous iron levels, n  5
for each group. *p  0.01 versus wild-type.
(C) Localization of SN ferric iron within dopa-
minergic neurons in the ferritin transgenics
as verified by double staining of Perls-posi-
tive SN cells with TH antibody. 1, 4magnifi-
cation of Perls staining in a representative
section of the SN region of a ferritin trans-
genic mouse; 2, 10 magnification of boxed
region in panel 1 highlighting position of a
TH dopaminergic SN neuron in this brain
area (arrow); 3, Perls staining of the dopamin-
ergic neuron highlighted in panel 2; 4, 40
magnification of the dopaminergic neuron
shown in panel 2 demonstrating TH positivity.
decreased by 22%  9.8% in the ferritin transgenic SN and Langston, 1989; Chiueh and Rauhala, 1998). Ani-
mals treated with MPTP exhibit several of the major(Figure 2B; wt  3.8  0.20 g/g SN tissue, Tg  2.7 
0.13 g/g SN tissue, n  4 animals per parameter, *p  hallmarks of PD, including a substantial decrease in
numbers of dopaminergic SN neurons. The damaging0.01), presumably due to its conversion to ferric during
oxidation and storage in ferritin. To assess whether the effect of MPTP administration also mirrors the disease
in that oxidative stress appears to play a major role inincreased ferric iron colocalized with dopaminergic SN
neurons, Perls staining was performed in conjunction ensuing neurodegeneration (Yong et al., 1986; Cassarino
et al., 1999), including a decrease in glutathione (GSH)with immunocytochemistry using an antibody specific
for TH (Figure 2C). Perls staining revealed that, in agree- levels, as has been reported to occur early in the course
of PD (Perry et al., 1982; Sian et al., 1994; Hung andment with previous reports (Benkovic and Connor, 1993;
Connor et al., 1994; Cheepsunthorn et al., 1998), ferric Lee, 1998; Desole et al., 1993; Lan and Jiang, 1997).
Both MPTP-induced increases in reactive oxygen spe-iron is predominantly localized within SN cells with the
appearance of oligodendrocytes in wild-type animals cies (ROS) and decreases in GSH levels were both found
to be prevented in the ferritin transgenics (Figures 3A(data not shown). The numbers of ferric iron-positive
cells were increased in the transgenic SN and were and 3B). Acute MPTP administration (4 20 mg/kg body
weight, every 2 hr) resulted in a 56%  4% increase infound to be localized within cell bodies and neuritic
processes of TH-positive SN cells (Figure 2C). Estima- ROS levels in wild-type SN (n  6 animals, *p  0.01),
while no significant change was detected in transgeniction of numbers of Perls-positive SN cells demonstrated
a 22.4% 4.7% increase in the transgenic animals (p animals (95%  4.0%, n  8 animals, **p 	 0.05). A
2.4%  0.3% decrease in SN GSH was observed at 20.01); these cells displayed the correct size, morphology,
and TH-positive expression of dopaminergic neurons. hr and a 10.0%  0.05% at 8 hr, respectively, after the
final MPTP injection in wild-type mice (n 6, *p 0.01),Systemic administration of the neurotoxin MPTP pro-
duces a clinical syndrome strikingly similar to PD (Tetrud while no significant change was observed in the ferritin
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Figure 3. Effects of Acute MPTP Administration on Levels of Oxidative Stress, Dopaminergic SN Neuronal Cell Number and Striatal (ST)
Dopamine and Its Metabolites in pTH-Ferritin Transgenics versus Wild-Type Littermates
(A) Percentage change in ROS levels in SN tissue 8 hr following acute MPTP administration, *p  0.01, untreated versus MPTP-treated wt;
**p 	 0.05, MPTP-treated Tg versus wt.
(B) Percentage change in GSH levels in SN tissue 2 hr and 8 hr following acute MPTP administration, *p  0.01, untreated versus MPTP-
treated wt at 2 and 8 hr; **p 	 0.05, MPTP-treated Tg versus wt at 2 and 8 hr.
(C) TH SN cell counts from transgenics versus nontransgenics 7 days following acute MPTP administration, *p  0.01, MPTP-treated versus
untreated wt; **p 	 0.05; untreated and MPTP-treated Tg versus MPTP-treated wt.
(D) ST DA, DOPAC, and HVA content in ferritin transgenic versus wild-type littermates 7 days following acute MPTP, *p  0.01, untreated
versus MPTP-treated wt; **p 	 0.05, MPTP-treated Tg versus wt.
transgenics (1.0%  0.5% at 2 hr and 0.5%  0.3% To test whether pharmacological iron chelation using
a reported well-tolerated bioavailable reagent wouldat 8 hr, respectively, n  8, **p 	 0.05).
To assess the effects of ferritin expression on acute have similar protective effects afforded by transgenic
expression of an iron-chelating molecule, we examinedMPTP-induced dopaminergic SN cell loss, stereological
TH cell counts were performed. TH cell numbers in the effects of the metal-chelating agent CQ on suscepti-
bility to acute MPTP administration. Total SN iron levelsthe nontransgenic SN were found to decrease by ap-
proximately 30%  5.2% following acute MPTP admin- were found to be reduced approximately 30% in the
CQ-fed versus saline-fed animals (Figures 4A and 4B),istration (Figure 3C; 10,900  800, saline-treated;
7,000 500, MPTP-treated, n5, *p0.01). In contrast, well within the reported nontoxic range (Yassin et al.,
2000). As with the ferritin transgenics, MPTP-mediatedno decrease was noted following acute MPTP adminis-
tration in the ferritin transgenics (11,100  600, saline- increases in SN oxidative stress and decreases in SN
GSH were found to be significantly attenuated followingtreated; 10,500 700, MPTP-treated, n 7, **p	 0.05).
To confirm the protection against TH SN cell loss in the CQ pretreatment (Figures 5A–5C). A 20% 3% increase
in levels of 4-hydroxynonenol (4-HNE)-protein conju-ferritin transgenic following acute MPTP administration,
levels of striatal dopamine (DA) and its metabolites 3,4- gates, a 15%  2% increase in protein carbonyl levels,
and a 18%  3% decrease in GSH were observed indihydroxyphenylacetic acid (DOPAC) and homovanillic
acid (HVA) were measured. Wild-type animals displayed control SN 24 hr following MPTP injection (n 5 animals
per assay, *p  0.01). However, no significant changessignificant depletion of DA, DOPAC, and HVA commen-
surate with decreased numbers of TH SN neurons (Fig- in any of these indices of oxidative stress were found
in the CQ-pretreated animals (n  6 animals, **p 	 0.05ure 3D; DA, DOPAC, HVA  100  3.0, 9.0  0.5, 10.0 
0.8 ng/mg protein in saline-treated and 20.0 0.6, 2.0 versus wt). To assess the affects of CQ pretreatment
on MPTP-induced dopaminergic SN cell loss, measure-0.4, 5.0  0.6 ng/mg protein in MPTP-treated, n  4,
*p  0.01). These losses were attenuated in the ferritin ments of both striatal dopamine levels and stereological
TH cell numbers were performed following acute treat-transgenics (DA, DOPAC, HVA 105 3.0, 10.0 0.54,
10.5  0.6 ng/mg protein in saline-treated and 95.0  ment with MPTP (Figures 5D and 5E). While reductions
in striatal dopamine levels in untreated controls were0.8, 7.0 1.0, 9.0  0.7 ng/mg protein in MPTP-treated,
n 5, **p	 0.05 compared to wt). The protective effects approximately 80% (121.8  25.6 versus 21.4  4.5
mg/g striatal tissue, *p 0.01 versus untreated control),of the ferritin transgene could not be explained by de-
creased conversion of MPTP to MPP following acute this loss was only 41% in animals pretreated with CQ
(147.2  10.6 versus 60.5  8.8 mg/g striatal tissue,administration (transgenic 143.04 18.02 ng/mg pro-
tein MPP, wild-type  109.77  22.03 ng/mg protein **p  0.01 versus Veh/MPTP). No significant difference
in striatal dopamine levels was observed between salineMPP, n  4, p 	 0.05).
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induced loss in motor activity was significantly attenu-
ated by either transgenic ferritin expression (Figure 6A,
30.86%  2.19% decrease in wt; 19.71%  1.61% de-
crease in transgenic versus untreated control, n  4,
p  0.01) or CQ pretreatment (Figure 6B, 36.43% 
11.7% decrease in vehicle-fed/acute MPTP; 13.55% 
2.6% decrease in CQ-fed/acute MPTP versus untreated
control, n 4, p 0.01) by 24 hr following the last MPTP
dose. In addition, CQ was also found to be protective
96 hr following the chronic MPTP treatment regime (Fig-
ure 6C, 24.95%  5.97% decrease, vehicle-fed/chronic
MPTP; 10.27%  3.10% decrease, CQ-fed/chronic
MPTP, n  4, p  0.01).
Discussion
MPTP-induced neurotoxicity has proven in the past to
be an invaluable tool for testing drug therapy in experi-
mental parkinsonism as a model for PD (Sedelis et al.,
2001; Beal, 2001). MPTP reproduces virtually all symp-
toms of the disease, including inhibition of mitochondrialFigure 4. Effects of CQ Pretreatment on Total SN Iron Content
complex I activity, decreased GSH and increased oxida-(A) Total SN iron content (g/mg tissue wet weight) measured via mass
tive stress levels in the SN, relatively selective neurode-spectrometry of vehicle (Veh) versus CQ-fed animals, *p  0.01.
generation of the dopaminergic nigrostriatal system,(B) SN iron levels measured via MRI in Veh versus CQ-fed animals,
*p  0.01. striatal dopamine depletion, and motor control deficits,
all of which can be reversed by dopamine substitution
therapy, the classic PD drug treatment. Its effects were
indeed originally discovered in humans as a conse-versus CQ-fed animals in the absence of MPTP treat-
ment, suggesting that CQ pretreatment alone has no quence of inadvertent injection that resulted in an acute
parkinsonism. MPTP does not perfectly model the disor-effect (Figure 5D). While SN TH cell numbers in un-
treated animals were decreased by 46% following acute der, particularly in terms of the acute nature of onset
using this drug and the absence of inclusion bodies inMPTP administration (15,346  1,471, saline-treated;
8,336  1,093, MPTP-treated, n  5, *p  0.01), only a rodents (Betarbet et al., 2002). However, an animal
model does not need to recapitulate every feature of the25% decrease was noted in the CQ-fed animals
(11,462  915, n  5, **p  0.01 versus MPTP-treated disease in order to be useful in evaluating the potential
therapeutic potential of a particular agent.controls). As with transgenic ferritin expression, the pro-
tective effects of CQ pretreatment were not explainable Elevated levels of brain iron similar to those reported
in PD have been shown to result in significantly higherby decreased conversion of MPTP to MPP (CQ-fed 
134.04  8.70 ng/mg protein MPP, saline-fed  levels of both oxidative stress and dopaminergic cell
loss following MPTP administration in vivo, suggesting138.15  6.63 ng/mg protein MPP, n  5, p 	 0.05).
In order to examine the effects of CQ pretreatment in that elevated iron can contribute to the toxicity of the
compound via an oxidative mechanism (Lan and Jiang,a different MPTP toxicity paradigm, we also assessed
toxin-induced dopaminergic SN cell loss following a 1997). Redox-available iron has been detected in mid-
brain Lewy bodies in postmortem parkinsonian brainschronic regime of MPTP treatment (5  20 mg/kg, 24
hr apart; Figure 5F; Vila et al., 2001). Following chronic (Castellani et al., 2000), and the oxidation state of iron
has been reported to change from ferrous to ferric withintreatment with MPTP, SN TH cell numbers in untreated
animals were decreased by 31% (10,143  701, saline- SN TH neurons during progression of the disease (Yo-
shida et al., 2001). Our data demonstrate that chelationtreated; 7,010  238, MPTP-treated, n  6, *p 	 0.01),
but only by 17% in the CQ-pretreated animals (8449  of iron via ferritin or CQ in a state that prevents it from
participating in oxidative events significantly attenuates503, n 5, **p	 0.01 versus MPTP-treated controls). No
difference in TH cell numbers was observed between toxicity of the parkinsonian-inducing agent MPTP.
These results definitively demonstrate the involvementvehicle- or CQ-fed animals prior to MPTP treatment
(10,143  701, saline-treated; 10,291  660, CQ-fed, of iron in MPTP-mediated neurodegeneration. These re-
sults, in addition, challenge the view that iron accumula-n  6, p 	 0.05), suggesting the CQ alone had no effect
on this parameter. tion is a late-stage, irreversible event in MPTP toxicity
and PD and suggests that iron chelation may be anFinally, we assessed whether either genetic or phar-
macological iron chelation provided protection against effective preventative therapy for progressive degenera-
tion associated with the disease.behavioral motor deficits associated with MPTP treat-
ment (Figure 6). Neither transgenic ferritin expression Transgenic expression of the heavy ferritin subunit
was found to prevent dopaminergic SN cell loss associ-nor CQ treatment alone was found to result in decreased
motor performance as assessed by rotorod (data not ated with MPTP toxicity. The heavy subunit contains
catalytic ferroxidase activity, which allows it to detoxifyshown). However, performance following acute MPTP
treatment was found to be decreased, and this MPTP- reactive ferrous iron and is the predominant form found
Neuron
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Figure 5. Protective Effects of CQ Pretreatment against MPTP-Mediated Oxidative Stress and Dopaminergic Cell Loss under Either Acute or
Chronic MPTP Dosing Regimes
(A and B) Levels of 4-HNE-protein conjugates (A) and protein carbonyl content (B) as assessed by slot blot analysis of SN tissue 24 hr following
acute MPTP or saline (Sal) administration in the absence or presence of CQ pretreatment, *p  0.01, Veh/MPTP versus Veh/Sal; **p 	 0.05,
CQ/Sal and CQ/MPTP versus Veh/Sal.
(C) Total SN GSH levels 24 hr following acute MPTP or saline administration  CQ pretreatment, *p  0.01, Veh/MPTP versus Vehl/Sal; **p 	
0.05, CQ/Sal and CQ/MPTP versus Veh/Sal.
(D) ST DA, DOPAC, and HVA content in saline versus CQ-fed mice 7 days following acute MPTP, *p  0.01, Veh/MPTP versus Veh/Sal; **p 	
0.05, CQ/Sal and CQ/MPTP versus Veh/Sal.
(E) TH SN cell counts from saline versus CQ fed 7 days following acute MPTP administration, *p  0.01, MPTP versus untreated wt; **p 
0.01 CQ/MPTP versus MPTP-treated wt.
(F) TH SN cell counts from saline versus CQ fed 7 days following chronic MPTP administration, *p  0.01, MPTP versus untreated wt; **p 
0.01 CQ/MPTP versus MPTP-treated wt.
in brain neurons (Harrison and Arosio, 1996; Connor et cal consequences (Curtis et al., 2001; Connor et al.,
2001; Thompson et al., 2001).al., 1995; Han et al., 2000). It is rapidly upregulated in
response to oxidative stress, and overexpression in vitro Like ferritin, CQ also has metal binding properties,
although it appears to act via chelation of both ferrousresults in increased resistance to H202-mediated insult
(Orino et al., 2001; Cozzi et al., 2000), suggesting that it and ferric iron rather than conversion of available ferrous
to bound unreactive ferric iron. It is lipophilic and there-may play an important role as a biological antioxidant
by sequestering iron that is normally free to participate in fore freely crosses the blood-brain barrier. CQ has re-
cently been shown to inhibit plaque formation and ac-oxidative events. Several recent reports have suggested
that diseases of iron overload may have their basis in companying behavioral declines in an AD transgenic
mouse model (Cherny et al., 2001; see commentary bymisregulation of iron storage by ferritin. A dominantly
inherited iron overload disease in a Japanese pedigree, Melov, 2002). We found that CQ given at similar concen-
trations and time periods found to be effective in thefor example, was recently attributed to a point mutation
in the iron response element (IRE) in the H ferritin gene AD mouse studies results in significant attenuation of
the neurotoxic effects of MPTP. CQ has been shown topromoter, which leads to increased binding affinity of
the iron regulatory protein (IRP), decreasing H ferritin reduce bioavailable brain iron in normal control mice
with no apparent adverse health or behavioral effectssynthesis and resulting in increased cytoplasmic iron
levels (Kato et al., 2001). A mutation in the gene encoding (current study; Yassin et al., 2000). CQ treatment also
does not result in depletion in systemic iron levels thatthe ferritin light subunit has also recently been reported
to cause a dominantly inherited adult-onset basal gan- could cause adverse physiological effects (Yassin et al.,
2000). This is in contrast to other currently used ironglia disease similar to PD due to a change in its confor-
mation that affects its ability to function as a stabilizer of chelators administered to patients with iron overload
conditions that have been shown to have toxic sidethe ferritin-iron core, resulting in increased iron release,
suggesting that iron excess can have serious neurologi- effects at the higher dosages needed to overcome the
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in addition, efficacious in delaying the course of the
disease. Acute administration of the compound at signif-
icantly higher dosages had previously been associated
with a subacute myelo-optic neuropathy (SMON), which
was primarily confined to Japan (Masters, 2002; Tsubaki
et al., 1971). SMON appears to resemble a subacute
accelerated form of B12 deficiency, and CQ has been
shown to lower levels of brain and serum vitamin B12
(Yassin et al., 2000). However, a causal relationship be-
tween SMON and CQ intake has not been established;
for example, CQ was used extensively in Japan for 20
years before the first cases of SMON were reported
(Meade, 1975; Nakae et al., 1973; Baumgartner et al.,
1979; Clifford Rose and Gawel, 1984). In light of this
possibility, the Alzheimer phase II clinical trials (Masters,
2002) were performed with B12 coadministration, and
dosages of the drug were kept to a fraction of those
dosages used previously that demonstrated neurotoxic
effects (e.g., Yoshimura et al., 1992; Tateishi, 2000). The
possible toxic effects of chronic CQ administration at
these dosages beyond the period of the trial, however,
have yet to be assessed.
Increases in reactive brain iron are not specific to PD
but are also seen in such diverse neurodegenerative
disorders as multiple system atrophy, Huntington’s dis-
ease, Alzheimer’s disease, progressive supranuclear
palsy, aceruloplasminemia, and Hallervorden-Spatz
(Dexter et al., 1991; Connor et al., 1992; Smith et al.,
1997; Gitlin, 1998; Janetzky et al., 1997). Misregulation
of iron metabolism resulting in iron accumulation, there-
fore, may be a general phenomenon contributing to the
progression of several neurodegenerative conditions.Figure 6. Protective Effects of Transgenic Ferritin Expression and
Pharmacological CQ Treatment against Motor Deficits Elicited by Brain iron accumulation along with increased ROS pro-
Either Acute or Chronic MPTP Treatment duction is part of the normal aging process, particularly
(A) Decreases in motor activity as assessed by rotorod in wt versus in the basal ganglia, and this in itself may contribute to
ferritin transgenic mice 24 hr following acute MPTP treatment. *p  the increased age-related susceptibility in a subset of
0.01, MPTP versus untreated wt; **p 	 0.01, MPTP-treated Tg ver- these diseases (Bartzokis et al., 1997; Zecca et al., 2001;
sus wt.
Christen, 2000; Thompson et al., 2001). Brain H ferritin(B) Decreases in motor activity in Veh versus CQ-fed mice 24 hr
levels are known to increase with age, likely as a protec-following acute MPTP treatment, *p  0.01, MPTP versus saline-
tive response to increasing iron levels; however, thistreated wt; **p  0.01, MPTP-treated CQ versus wt.
(C) Decreases in motor activity in saline versus CQ-fed mice 96 hr increase does not appear to occur in either PD or AD
following chronic MPTP mice, *p 0.01, MPTP versus saline-treated brains (Connor et al., 1995; Zecca et al., 2001; Thompson
wt; **p  0.01, MPTP-treated CQ versus wt. et al., 2001). Although it has been previously speculated
that increasing the iron loading of ferritin may increase
the risk of free radical damage (Double et al., 1998;
compounds’ low lipid solubility that impair their ability Griffiths et al., 1999), our data in contrast suggest that
to cross the blood-brain barrier (Porter and Huehns, increased ferritin is in fact neuroprotective. Indeed, ferri-
1989; Marciani et al., 1991). It should be noted that it tin has recently been reported to normally be absent in
cannot be excluded that the protective effects of CQ dopaminergic SN neurons, and this may, in combination
may be due in part to previously reported CQ-mediated with other factors such as elevated iron levels, contrib-
depletions in brain copper levels, as copper can act to ute to their susceptibility to oxidative stress (Moos et
facilitate Fe2 toxicity (Cherny et al., 2001); however, al., 2000). It is of interest in this regard that SN levels of
copper levels, unlike iron, have not been shown to be ferritin in humans have been reported to actually be
elevated in PD. No adverse effects were attributable to decreased in PD patients compared to age-matched
CQ administration in our study at a similar dosage (g/kg controls, although this is somewhat controversial (Reid-
body weight) to that used in the previous transgenic erer et al., 1989; Jellinger et al., 1990; Dexter et al.,
APP study (Huang et al., 1999; Bush, 2000; Cherny et 1991; Jenner et al., 1992; Mann et al., 1994). Extensive
al., 2001). Results from a recent small two-year double- elimination of iron from the brain is not desirable, as it
blind phase II trial assessing the efficacy of CQ as a is an abundant brain metal essential for several normal
possible treatment for AD suggest that oral administra- metabolic functions including the synthesis and release
tion of the agent accompanied by B12 supplementation of dopamine in the SN (Beard et al., 1993; Glinka et al.,
is well tolerated in humans over the period of the trial 1996; Connor et al., 2001; Thompson et al., 2001). In
at similar dosages to those used in both the previous addition, its deficiency during development has been
associated with neurobehavioral dysfunction (Connor etAPP transgenic and in our current MPTP study and were,
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samples encompassing SNc, SNr, and red nucleus were performedal., 1995). However, our data suggest that chelators such
(IPLab Spectrum, Scientific Image Processing from Scanalytics,as ferritin or CQ, which can remove excess iron without
Inc.; Morgan et al., 1999). Intensity was normalized using corticalapparent interference with its normal functions in the
white matter as control.
adult nervous system system, may postpone or prevent
the progression of such neurological diseases as PD Spectrophotometric Analysis of Bioavailable Ferrous Iron
(Gassen and Youdim, 1997). Levels of ferrous iron available to bind ferrozine were determined in
dissected SN tissue spectrophotometrically at 578 nm as previously
Experimental Procedures described (Agrawal et al., 2001).
Mouse Studies Ferric Iron Histochemistry (Perls)
Mice were housed according to standard animal care protocols, fed Coronal sections from brains of adult animals were subjected to
ad libitum, kept on a 12 hr light/dark cycle, and maintained in a formalin fixation and Perls staining using potassium ferrocyanide
pathogen-free environment in the Buck Institute Vivarium. Animals as previously described (Hill and Switzer, 1984). The percentage
used for studies were young adults (2–6 months of age). Ferritin area covered by ferric-ferrocyanine product was assessed by Cam-
transgenic mice were generated via injection of an 8.3 kb Hind III era Luminace Drawing.
DNA fragment containing 4.8 kb of 5 upstream sequences from the
rat TH gene (Banerjee et al., 1992), 2.6 kb of human genomic ferritin
ROS by DCF Fluorescence
DNA encompassing the 4 coding region exons (Hentze et al., 1986),
Animals were i.p. injected with either 30 mg/kg body weight MPTP
and 3 SV40 splice and polyadenylation sequences into fertilized
or saline. Eight hours after injection, synaptosomal fractions were
B6D2 mouse embryos to create pTH-ferritin transgenic founder ani-
prepared from the SN and used for DCF analysis (Ali et al., 1992).
mals. For CQ studies, C57Bl mice were obtained from Jackson Labs
Fluorescence was monitored on a Turner spectrofluorometer with
and randomized for therapy trials. CQ was suspended in saline and
an excitation wavelength of 448 mm and an emission wavelength
delivered via oral gavage at a daily dosage of 30 mg/kg as previously
of 525 nm. Protein was normalized by the Bradford method.
described for a period of 8 weeks (Cherny et al., 2001); controls
received vehicle alone. For acute MPTP studies, mice were treated
GSH Levelswith either 4  20 mg/kg, 2 hr apart or 2  20 mg/kg, 12 hr apart
Following MPTP or saline injection, GSH levels were measured inof the toxin, and SN or ST samples taken at the times specified for
the SN by the method of Griffith (1980).various analyses. For chronic MPTP studies, mice were treated with
5  20 mg/kg MPTP, 24 hr apart, and samples taken at specified
Histology and Neuron Countstimes for analyses.
Neuronal counts were performed on TH-positive SN neurons using
the unbiased dissector method (West, 1993). Fixed coronal brainSouthern Blot Analysis
sections (40 m) were immunostained with TH antibody (1:500 dilu-Genomic DNA from ferritin founders was digested with Xba I, sepa-
tion, Chemicon) and coverslipped in aqueous medium, and THrated on a 1% agarose gel, transferred to Hybond (Amersham), and
cells counted from a total of 15–20 sections in each field per brainhybridized with a 32P-labeled 2.6 kb Xba I-EcoRI ferritin genomic
(i.e., every second section) at a magnification of 100 using thefragment. Founder animals positive for the transgene were bred out
optical fractionator approach.to create lines for analysis; nontransgenic littermates were used as
negative controls.
Striatal Dopamine/DOPAC and MPP Levels
Animals were injected with either 15 mg/kg body weight MPTP orWestern/Slot Blot Analyses
saline every 2 hr for 4 doses. Dopamine, DOPAC, and HVA or MPPSN were dissected and homogenized in 10 mM HEPES-KOH (pH
from dissected striata were analyzed by HPLC using a 5 m C-187.2), 2 mM EDTA, 0.1% CHAPS, 5 mM dithiothreitol (DTT), 1 mM
reverse phase column and precolumn (Brownlee Labs) followed byphenylmethylsulfonyl fluoride, 10g/ml pepstatin A, 10g/ml aprot-
electrochemical detection with a glassy carbon electrode (Klivenyiinin, and 20 g/ml leupeptin (Nicholson et al., 1995). Fifteen micro-
et al., 2000).grams of total protein from each sample was either run on a 15%
SDS-PAGE gel (BioRad) and transferred to nitrocellulose membrane
or directly slotted onto membrane. Membranes were incubated with SN Iron Levels by Mass Spectrometry
10–50 g/ml primary antibody (heavy chain human ferritin mono- SN was dissected and snap frozen in liquid nitrogen and the wet
clonal, Ramco Laboratories; anti-HNE Michaels adduct rabbit poly- weight was determined; then, it was lyophilized and the dry weight/
clonal, Calbiochem; anti-DNP rabbit polyclonal, Intergen), followed tissue was measured. Preweighed lypholized samples were next
by horseradish peroxidase-conjugated secondary antibody (Vector taken up in 0.1 ml of concentrated nitric acid (Aristar, BDH) and
Laboratories). Autoradiography was performed with enhanced allowed to digest overnight. The samples were then heated to 80
C
chemiluminescence (Amersham Pharmacia). For 4HNE-protein con- for 15 min and cooled, and 0.1 ml 30% hydrogen peroxide added.
jugates and protein carbonyls, relative optical band density were Samples were heated to 70
C for 15 min, cooled, and diluted 1/40
quantified using a ChemiImager 5500 (Alpha Innotech Corporation). into 1% HN03 for analysis by inductively coupled plasma mass spec-
Reported values are the results of three independent experiments. trometry (ICP-MS) using an Ultramass 700 (Varian) in peak-hopping
mode with 0.100 AMU spacing, 1 point per peak, 50 scans per
replicate, 3 replicates per sample. Preparation blanks processed inImmunocytochemistry
a similar manner were used as controls. Plasma flow was 15 l/minAnimals were cardiac-perfused with phosphate-buffered saline
with auxiliary flow of 1.5 l/min, RF power was 1.2 kW, and sample(PBS) followed by 10% formalin, and brains were removed and
was introduced at a flow rate of 0.88 l/min.postfixed for 15 hr followed by 30% sucrose and sectioning at 40m
on the coronal plane. ICC was performed as previously described
(Andersen et al., 1994). Specific primary antibodies were applied and Rotorod Performance
visualized with fluorescence (Streptavidin-Cy3 for red fluorescence Motor activity was measured via rotorod performance utilizing an
and Streptavidin-Cy2 for green fluorescence, Jackson Immuno- Accelerated Rota-Rod for mice 7650 (UGO Basil, Italy) with a rod
chemicals). diameter of 3 cm according to the manufacturer’s instructions. The
mice were allowed to acclimatize for 20 s at the lowest speed, i.e.,
4 rpm, and then the rotor was allowed to accelerate to 40 rpm duringSN Iron Levels by Magnetic Resonance Imaging (MRI)
MRI studies were performed using a Bruker AMX500 11.7 tesla MRI a period of 5 min. Fall of the animal from the rod was taken as the
end point of run. Each animal was tested three times on each testsystem as previously described (Gilissen et al., 1998). Brains were
fixed as described above and MRI performed in the coronal plane. day with an hour of rest between consecutive runs. Animals were
tested 1, 2, 3, 4, and 7 days post final MPTP treatment.Comparisons of SN hypointensity (dark area) on T2-weighted MR
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